Biostax Corp. (BTAX)

Overview

Biostax Corp., previously known as Immune Therapeutics, Inc., is a biopharmaceutical company with a focus on acquiring, developing, and commercializing a wide range of pharmaceutical and biotechnological products. Its operational strategies are directed towards advancing innovative treatments primarily for HIV/AIDS through its leading investigational drug candidate, Lodonal. Aside from its core focus, Biostax Corp. is broadening its reach into digital health technologies and various therapeutic areas, including autoimmune diseases and liver conditions. Rebranded in October 2023, the company is headquartered in Orlando, Florida and boasts a strategic licensing agreement with Cytocom Inc., signifying its commitment towards advancing healthcare solutions.

Products and Services

• Lodonal: This is Biostax Corp.'s flagship investigational drug, an immune system regulator designed for the once-daily management of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Its mechanism promises a groundbreaking approach in the treatment and management of these conditions.
• Global Telehealth Platform: In response to the growing demand for digital health services, Biostax Corp. has ventured into telehealth with a platform that aims to provide accessible healthcare services. This platform emphasizes the delivery of medical consultations and health-related services through digital channels.
• Medtech Asset: Embracing technological innovations, the company is developing a Medtech asset focused on employing blockchain and smart contracts. This program is in its early development stages with the goal of securely managing prescriptions and electronic health records, highlighting Biostax Corp.'s commitment to advancing healthcare with technology.
• JKB-122: JKB-122 is an investigational small molecule, classified as a long-acting toll-like receptor 4 (TLR4) antagonist. It is under development for conditions such as autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), showcasing Biostax Corp.'s involvement in treating liver diseases.
• Low Dose Naltrexone: This compound is under investigation for its immune-modulating benefits, with potential applications across a diverse range of conditions including cancer, pain management, autoimmune diseases, and anti-aging therapies. The formulation underscores the company’s dedication to exploring innovative treatments beyond its primary focus.
• Hyperphosphatemia Treatment Programs: Additionally, Biostax Corp. is developing treatment programs for hyperphosphatemia, reflecting its ambition to address a variety of healthcare needs and patient populations.